Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.5 USD | -1.89% | +5.23% | -24.38% |
May. 15 | Legend Expects to Log Profit in 2026 | MT |
May. 14 | HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating | MT |
Evolution of the average Target Price on Legend Biotech Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Legend Biotech Corporation
HC Wainwright | |
RBC Capital Markets | |
Scotiabank | |
Cantor Fitzgerald | |
UBS | |
Raymond James | |
Barclays | |
Morgan Stanley | |
BTIG | |
William Blair & Co. | |
Daiwa Securities | |
BMO Capital | |
JPMorgan Chase | |
Piper Sandler | |
Cowen | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- LEGN Stock
- Consensus Legend Biotech Corporation